Regeneron officer McCourt proposes $545K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Regeneron Pharmaceuticals, Inc. (REGN) officer Marion McCourt reported a proposed sale of 566 common shares, with an aggregate market value of $545,239.12 and an approximate sale date of November 16, 2026. The shares were acquired through RSA vesting on December 12, 2023.
The notice lists February 17, 2026 as the plan adoption or instruction date in the Rule 10b5-1 section.
Key Figures
Key Terms
RSA Vesting financial
Rule 10b5-1 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Marion McCourt's recent REGN stock sales?
What Rule 10b5-1 date does REGN's notice report?
AI-generated analysis. How Rhea-AI works. Not financial advice.